High rate of non-target lesions in metastatic castration-resistant prostate cancer usually limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and this has led to a growing interest in using PET/computed tomography (CT). We prospectively investigated the role of (18)F-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel.

Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers

MAINES, Francesca;CAFFO, Orazio;Bria, Emilio;CHIERICHETTI, Franca;TORTORA, GIAMPAOLO;GALLIGIONI, Enzo
2016-01-01

Abstract

High rate of non-target lesions in metastatic castration-resistant prostate cancer usually limits applicability of Response Evaluation Criteria in Solid Tumors (RECIST) criteria, and this has led to a growing interest in using PET/computed tomography (CT). We prospectively investigated the role of (18)F-choline (FCH)-PET/CT in patients receiving enzalutamide after docetaxel.
2016
18F-choline PET; castration-resistant prostate cancer; enzalutamide; response; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Choline; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Phenylthiohydantoin; Positron-Emission Tomography; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tissue Distribution; Treatment Outcome
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/953626
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 30
  • ???jsp.display-item.citation.isi??? 29
social impact